Rita A. Sakr
Research Subjects
Research Interests
Rita A. Sakr has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Adriana Heguy
Department of Pathology, NYU Grossman School of Medicine, New York, USA
1 shared publication Aphrothiti J. Hanrahan
1 shared publication- Aydah Al-Awadhi
Tawam Hospital
1 shared publication - Barry S. Taylor
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication - Carol Aghajanian
Memorial Sloan Kettering Cancer Center, New York, NY, USA
1 shared publication - Chris Sander
Department of Systems Biology, Harvard Medical School, Boston, USA
1 shared publication
Latest Publications
- Open Access
- 18 September 2024
- Published by Springer Nature
- p. 625-628
Cancer Survivorship Programs in the UAE
Due to demographics, greater early detection, and improved treatment, there are more cancer survivors today. Hence, it becomes important to provide these patients with a survivorship care plan with tailored check-ups and routine follow-ups to ensure their physical and psychosocial well-being and mitigate the possible long-term effects due to the disease itself and the treatments provided. In the United Arab Emirates, cancer survivorship programs and dedicated clinics have yet to be established as an integral part of caring for cancer patients. In this chapter, we will shed light on the unmet need to optimize holistic cancer care delivery and develop a national survivorship strategy tailored to cancer, cultural, and population characteristics.
- 18 September 2024
- Published by Springer Nature
- p. 625-628
Open AccessCancer Survivorship Programs in the UAE
Due to demographics, greater early detection, and improved treatment, there are more cancer survivors today. Hence, it becomes important to provide these patients with a survivorship care plan with tailored check-ups and routine follow-ups to ensure their physical and psychosocial well-being and mitigate the possible long-term effects due to the disease itself and the treatments provided. In the United Arab Emirates, cancer survivorship programs and dedicated clinics have yet to be established as an integral part of caring for cancer patients. In this chapter, we will shed light on the unmet need to optimize holistic cancer care delivery and develop a national survivorship strategy tailored to cancer, cultural, and population characteristics.
- Open Access
- 18 September 2024
- Published by Springer Nature
- p. 235-243
Genetic Testing for Cancer Risk in the UAE
Hereditary cancers are estimated to account for 10% of all cancers. Clinical genetics initially provided genetic testing to cancer patients and/or those with a strong family history of cancer. Hereditary cancer gene testing became more widely available as a result of research into inherited genes and the revolutionary development of genetic testing technologies. As a result, testing has been expanded to include medical specialties other than clinical genetics. The increased testing rate resulted in the identification of more patients with pathogenic mutations, but it also resulted in a very high detection rate of variants of uncertain significance, which can cause further confusion among families and distress in patients. Therefore, a crucial suggestion would be that multigene testing should be considered only after proper evaluation for clinical suspicion of hereditary cancer susceptibility, which would be best offered by clinical genetics and/or doctors trained in oncogenetics.
- 18 September 2024
- Published by Springer Nature
- p. 235-243
Open AccessGenetic Testing for Cancer Risk in the UAE
Hereditary cancers are estimated to account for 10% of all cancers. Clinical genetics initially provided genetic testing to cancer patients and/or those with a strong family history of cancer. Hereditary cancer gene testing became more widely available as a result of research into inherited genes and the revolutionary development of genetic testing technologies. As a result, testing has been expanded to include medical specialties other than clinical genetics. The increased testing rate resulted in the identification of more patients with pathogenic mutations, but it also resulted in a very high detection rate of variants of uncertain significance, which can cause further confusion among families and distress in patients. Therefore, a crucial suggestion would be that multigene testing should be considered only after proper evaluation for clinical suspicion of hereditary cancer susceptibility, which would be best offered by clinical genetics and/or doctors trained in oncogenetics.
- Open Access
- 14 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (10) , 2908
Evaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis
Background/Objectives: De-escalation of axillary surgery is made possible by advancements in both neoadjuvant systemic therapy (NST) and in localisation technology for breast lesions. Magseed®, developed in 2013 by Dr. Michael Douk of Cambridge, United Kingdom, is a wire-free localisation technology that facilitates the localisation and retrieval of lymph nodes for staging. Targeted axillary dissection (TAD), which entails marked lymph node biopsy (MLNB) and sentinel lymph node biopsy (SLNB), has emerged as the preferred method to assess residual disease in post-NST node-positive patients. This systematic review and pooled analysis evaluate the performance of Magseed® in TAD. Methods: The search was carried out in PubMed and Google Scholar. An assessment of localisation, retrieval rates, concordance between MLNB and SLNB, and pathological complete response (pCR) in clinically node-positive patients post NST was undertaken. Results: Nine studies spanning 494 patients and 497 procedures were identified, with a 100% successful deployment rate, a 94.2% (468/497) [95% confidence interval (CI), 93.7–94.7] localisation rate, a 98.8% (491/497) retrieval rate, and a 68.8% (247/359) [95% CI 65.6–72.0] concordance rate. pCR was observed in 47.9% (220/459) ) [95% CI 43.3–52.6] of cases. Subgroup analysis of studies reporting the pathological status of MLNB and SLNB separately revealed an FNR of 4.2% for MLNB and 17.6% for SLNB (p = 0.0013). Mean duration of implantation was 37 days (range: 0–188). Conclusions: These findings highlight magnetic seed localisation’s efficacy in TAD for NST-treated node-positive patients, aiding in accurate axillary pCR identification and safe de-escalation of axillary surgery in excellent responders.
- 14 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (10) , 2908
Open AccessEvaluating Magnetic Seed Localization in Targeted Axillary Dissection for Node-Positive Early Breast Cancer Patients Receiving Neoadjuvant Systemic Therapy: A Comprehensive Review and Pooled Analysis
Background/Objectives: De-escalation of axillary surgery is made possible by advancements in both neoadjuvant systemic therapy (NST) and in localisation technology for breast lesions. Magseed®, developed in 2013 by Dr. Michael Douk of Cambridge, United Kingdom, is a wire-free localisation technology that facilitates the localisation and retrieval of lymph nodes for staging. Targeted axillary dissection (TAD), which entails marked lymph node biopsy (MLNB) and sentinel lymph node biopsy (SLNB), has emerged as the preferred method to assess residual disease in post-NST node-positive patients. This systematic review and pooled analysis evaluate the performance of Magseed® in TAD. Methods: The search was carried out in PubMed and Google Scholar. An assessment of localisation, retrieval rates, concordance between MLNB and SLNB, and pathological complete response (pCR) in clinically node-positive patients post NST was undertaken. Results: Nine studies spanning 494 patients and 497 procedures were identified, with a 100% successful deployment rate, a 94.2% (468/497) [95% confidence interval (CI), 93.7–94.7] localisation rate, a 98.8% (491/497) retrieval rate, and a 68.8% (247/359) [95% CI 65.6–72.0] concordance rate. pCR was observed in 47.9% (220/459) ) [95% CI 43.3–52.6] of cases. Subgroup analysis of studies reporting the pathological status of MLNB and SLNB separately revealed an FNR of 4.2% for MLNB and 17.6% for SLNB (p = 0.0013). Mean duration of implantation was 37 days (range: 0–188). Conclusions: These findings highlight magnetic seed localisation’s efficacy in TAD for NST-treated node-positive patients, aiding in accurate axillary pCR identification and safe de-escalation of axillary surgery in excellent responders.
- 1 June 2019
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 13 (2) , 89-94
Style d’attachement et ajustement psychosocial au cancer du sein : quelles implications pour la communication patient–personnel soignant ?
Objectif : Notre recherche étudie l’influence du style d’attachement sur le processus d’ajustement psychosocial au cancer du sein, dans différents domaines : contexte médical, relation à la médecine et aux soins, vie professionnelle, vie domestique, relations familiales élargies et amicales, vie sociale et récréative ainsi que détresse psychologique actuelle. L’étude porte sur un groupe de patientes libanaises âgées entre 35 et 55 ans. L’objectif est de mieux connaître quelles patientes sont les plus à risque de montrer des difficultés d’ajustement et d’envisager un accompagnement psychologique qui leur soit adéquat ainsi que de souligner les compétences de communication patientes–personnel soignant. Matériel et méthode : Nous avons adopté la méthode comparative. Notre échantillon est constitué de 60 patientes atteintes de cancer du sein, divisées en deux groupes (patientes sécurisées et patientes insécurisées) selon l’échelle « Revised Adult Attachment Scale (RAAS) (Collins, 1996) — Close Relationships Version ». L’ajustement psychosocial au cancer a été déterminé par le « Psychosocial Adjustment to Illness Scale (PAIS) ». Résultats : L’étude a montré que les femmes atteintes de cancer du sein dont l’attachement est sécurisant présentent un meilleur ajustement à la maladie que celles dont l’attachement est insécurisant, et ce dans les différents domaines déjà cités. Conclusion : La compréhension des styles et des besoins d’attachement des patientes atteintes de cancer du sein aide les professionnels de santé à être plus efficaces dans leur réponse et dans leur manière de se comporter avec les patientes, favorisant ainsi leur ajustement à la maladie, surtout pour celles dont l’attachement est insécurisant.
- 1 June 2019
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 13 (2) , 89-94
Style d’attachement et ajustement psychosocial au cancer du sein : quelles implications pour la communication patient–personnel soignant ?
Objectif : Notre recherche étudie l’influence du style d’attachement sur le processus d’ajustement psychosocial au cancer du sein, dans différents domaines : contexte médical, relation à la médecine et aux soins, vie professionnelle, vie domestique, relations familiales élargies et amicales, vie sociale et récréative ainsi que détresse psychologique actuelle. L’étude porte sur un groupe de patientes libanaises âgées entre 35 et 55 ans. L’objectif est de mieux connaître quelles patientes sont les plus à risque de montrer des difficultés d’ajustement et d’envisager un accompagnement psychologique qui leur soit adéquat ainsi que de souligner les compétences de communication patientes–personnel soignant. Matériel et méthode : Nous avons adopté la méthode comparative. Notre échantillon est constitué de 60 patientes atteintes de cancer du sein, divisées en deux groupes (patientes sécurisées et patientes insécurisées) selon l’échelle « Revised Adult Attachment Scale (RAAS) (Collins, 1996) — Close Relationships Version ». L’ajustement psychosocial au cancer a été déterminé par le « Psychosocial Adjustment to Illness Scale (PAIS) ». Résultats : L’étude a montré que les femmes atteintes de cancer du sein dont l’attachement est sécurisant présentent un meilleur ajustement à la maladie que celles dont l’attachement est insécurisant, et ce dans les différents domaines déjà cités. Conclusion : La compréhension des styles et des besoins d’attachement des patientes atteintes de cancer du sein aide les professionnels de santé à être plus efficaces dans leur réponse et dans leur manière de se comporter avec les patientes, favorisant ainsi leur ajustement à la maladie, surtout pour celles dont l’attachement est insécurisant.